An observational study in Childhood Obesity and Morbid Obesity, sponsored by Columbia University. Recruiting at 2 sites in United States. Open to participants aged 2 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-10-21.
Sponsored by Columbia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 558 studies in Pediatric Obesity with a site in United States — 72 open to participants now, 109 under way, 3 of them phase 3. Pediatric Obesity · United States.
Among the 558 studies in Pediatric Obesity with a site in United States, this one is the 79th largest by planned enrollment of the 81 observational ones that give a count, is one of 22 that started in 2015, is one of 82 observational ones, reaches primary completion later than 28 of the 108 other live ones, and was the 152nd registered.
1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.
Browse Pediatric Obesity studies →72 of the 558 studies in Pediatric Obesity with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 10–15
Children's Hospital Los Angeles · Sites in United States
Ages 12–18
Virginia Commonwealth University · Sites in United States
Ages 12–15 · Healthy volunteers
University of Michigan · Sites in United States
Ages 4 mo+ · Healthy volunteers
Russell McCulloh, MD · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.
This study: 2 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
558 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 27 · Phase 3 10 · Phase 4 11
First in 1998; this study’s year is marked. 22 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 179 across 236 observational studies indexed under Pediatric Obesity.
Median enrollment 95 across the 475 interventional studies, 120 across the 81 observational. Of the 419 that completed or were terminated, 116 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 558 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 6 studies filed under Pediatric Obesity — fewer than ten, so there is no comparison to draw.
39 of the studies in Pediatric Obesity with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04974554Medical University of South CarolinaFIT Families Multicomponent Obesity Intervention for African American Adolescents | 2026-11-30 |
| NCT06810557Temple UniversityBrief Behavioral Sleep Intervention for Obesity Prevention in Primary Care | 2026-11-30 |
| NCT04971044Vanderbilt University Medical CenterCompetency Based Approaches for Community Health 2 | 2026-12 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT04128995Children's Hospital Medical Center, CincinnatiSurgical or Medical Treatment | 2026-12 |
Add all 39 to your calendar (.ics) → With an account.
Among the 558 studies in Pediatric Obesity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rapid onset Obesity, Hypoventilation, Hypothalamic dysfunction and Autonomic Dysregulation (ROHHAD) is a syndrome named in 2007. The hallmark of the syndrome is the rapid onset obesity and dysregulation of central ventilation. There is little information about the metabolic changes that lead to the rapid onset obesity in these children. The investigators would like to study the metabolic phenotype of these children to understand the disturbances in energy balance that lead to the rapid onset obesity.
Late-onset hypoventilation syndrome with hypothalamic dysfunction was first described in 1965 and renamed to ROHHAD syndrome in 2007 by Ize-Ludlow et al.
The hallmark of ROHHAD syndrome is rapid-onset obesity starting at approximately 1.5 years of age with weight gain of 12-20 kg/year, central hypoventilation distinct from the obstructive hypoventilation caused by obesity, hyperphagia, a spectrum of pituitary hormonal dysfunction, and autonomic disturbances including temperature, blood pressure, and nociception abnormalities. Some children have been noted with developmental and behavioral abnormalities. Tumors of neural crest origin have been identified in 25-33% of the patients. The etiology of ROHHAD syndrome and the cause of rapid onset obesity is unknown.
The aims of this study are to understand the whole transcriptome profiling of patient specific induced pluripotent cell (iPSC) derived hypothalamic neurons to understand the transcriptional level changes that give rise to the manifestations seen in ROHHAD syndrome.
Aim 1. Generate patient specific iPSC-derived hypothalamic neurons from children with ROHHAD syndrome and their unaffected first degree relatives.
Aim 2: Compare the whole transcriptome profiling of the patient derived cells compared to those of unaffected relatives and reference datasets to understand the differences in transcriptome that gives rise to ROHHAD syndrome.
Aim 3: Selected patients may be invited to participate for detailed metabolic phenotyping to understand the mechanisms of excessive weight gain.
Children diagnosed with ROHHAD (Rapid onset Obesity, Hypoventilation, Hypothalamic dysfunction, Autonomic Disturbances), and their first degree relatives.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians. The investigators will perform transcriptome profiling in this group.
Diagnostic Test: Transcriptome profiling
Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.
Diagnostic Test: Transcriptome profiling
The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
Changes in the transcriptome profile of hypothalamic cells of children with ROHHAD syndrome compared to their unaffected first degree relatives.
The investigators will perform whole transcriptome profiling of iPSC-derived hypothalamic neurons and compare the whole genome sequencing to identify the changes that may give rise to the disease.
Time frame: 2 year
Not enrolling at this site.
The record gives a start of Nov 2015, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.